Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 9-Aminocamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | GLA | P06280 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 9-Aminocamptothecin SCHEMBL26578 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| Rs-9-Aminocamptothecin SCHEMBL8715088 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| Rs-9-Aminocamptothecin SCHEMBL27705522 | 0.96 | TOP1 (0.92) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL25932523 | 0.92 | TOP1 (0.84) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1006662 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL27561956 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL23270615 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1062768 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL29664993 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1301708 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 772 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4654972-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4654970-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4654959-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| CN-115737833-B | Camptothecine polypeptide antitumor drug conjugate and preparation method and application thereof | 苏州久蓝生物医药有限公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | claimed |
| EP-4045087-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2022-08-24 | — | — | EP | claimed |
| WO-2022140289-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | claimed |
| US-20220135982-A1 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-05 | — | — | US | claimed |
| EP-3968962-A1 | METHODS OF MAKING NANOCRYSTALS WITH ENHANCED BIOLOGICAL AVAILABILITY AND FORMULATION FOR SUCH NANOCRYSTALS PREPARATION FOR USE IN ANTICANCER THERAPY | Tomas Bata University In Zlín (CZ) | 2022-03-23 | — | — | EP | claimed |
| WO-2021245539-A9 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | 주식회사 비아이케이테라퓨틱스 | 2022-03-17 | — | — | WO | claimed |
| US-11266677-B2 | Methods for treatment or prevention of leukemia | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | claimed |
| CN-114099469-A | Composite nano-drug carrier and preparation method and application thereof | 齐齐哈尔医学院 | 2022-03-01 | — | — | CN | claimed |
| US-11246942-B2 | Meditopes and meditope-binding antibodies and uses thereof | CITY OF HOPE (US) | 2022-02-15 | — | — | US | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246942-B2 | Meditopes and meditope-binding antibodies and uses thereof | FCGR3B, FCGR2A, FCGR1A | TOP1 3379/4885KDM4E 1721/4885RECQL 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.